Arbea Leire, Coma-Canella Isabel, Martinez-Monge Rafael, García-Foncillas Jesús
Radiation Oncology Division, Department of Oncology, Clinica Universitaria, University of Navarra, Avda, Pio XII s/n. 31080, Spain.
World J Gastroenterol. 2007 Apr 14;13(14):2135-7. doi: 10.3748/wjg.v13.i14.2135.
5-Fluorouracil (5-FU) is the most frequently used chemotherapy agent concomitant with radiotherapy in the management of patients with rectal cancer. Capecitabine is an oral fluoropyrimidine that mimics the pharmaconkinetics of infusional 5-FU. This new drug is replacing 5-FU as a part of the combined-modality treatment of a number of gastrointestinal cancers. While cardiac events associated with the use of 5-FU are a well known side effect, capecitabine-induced cardiotoxicity has been only rarely reported. Here, we reviewed the case of a patient with rectal cancer who had a capecitabine-induced coronary vasospasm. The most prominent mutation of the dihydropyrimidine dehydrogenase gene was also analyzed.
5-氟尿嘧啶（5-FU）是直肠癌患者治疗中最常与放疗联合使用的化疗药物。卡培他滨是一种口服氟嘧啶，其药代动力学与静脉输注5-FU相似。这种新药正在取代5-FU，成为多种胃肠道癌症联合治疗的一部分。虽然与使用5-FU相关的心脏事件是一种众所周知的副作用，但卡培他滨引起的心脏毒性仅有很少的报道。在此，我们回顾了一例直肠癌患者发生卡培他滨诱导的冠状动脉痉挛的病例。同时还分析了二氢嘧啶脱氢酶基因最显著的突变情况。
